F2R and atherosclerosis: Finally, the inhibition thrombin-induced platelet aggregation through PAR-1 with vorapaxar has been investigated in the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events—Thrombolysis in Myocardial Infarction (TRA-2°P-TIMI 50) which enrolled a broad population of patients with ASCVD [17].